Navigation Links
Anesiva to Present at BIO InvestorForum on October 11, 2007
Date:10/5/2007

SOUTH SAN FRANCISCO, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that John P. McLaughlin, the company's chief executive officer, will present at the Biotechnology Industry Organization's "BIO InvestorForum 2007" on Thursday, October 11, 2007 at 9:30 am PDT in San Francisco.

To access the live webcast or the subsequent archived recording, log on to http://www.anesiva.com and go to the Investors page, and click on Events. Please connect to Anesiva's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Anesiva and its Diverse Portfolio of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has one FDA-approved product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, to reduce pain associated with peripheral venous access procedures in children three to 18 years of age. The second product in Anesiva's pipeline, Adlea(TM) (formerly 4975), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Early this week, Team Iconic at ... of Nestlé KITKAT as the first global confectionery brand sourced from 100% sustainable cocoa. ... the quality of their product, through activities that focus on better farming, better lives ...
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing series of ... Each webinar features a dynamic expert and thoughtful presentation to give attendees a ... facilities. Both events are free to attend, but registration is required. ...
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency care to ... this can leave patients with dental emergencies at risk of losing a tooth or ... dental care. , Common dental emergencies include:, , Avulsed ...
(Date:2/10/2016)... ... 10, 2016 , ... Intalere’s 2016 Executive Forum, taking place ... the country’s top healthcare executives to share insights on transformational strategies to drive ... is the provider-centric perspective, experience, expertise and strategy shared by the participants,” said ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Emmy award winner and inspirational speaker Jan Fox will serve as keynote speaker ... Boldly will provide participants with tools to more effectively communicate with their own ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... OR AKIVA, Israel , February 10, ... Ltd., a leader in the field of cartilage repair, ... on February 5, 2016. The $15 million investment was ... leading Chinese pharmaceutical manufacturer, and was joined by existing ... Financial Holdings and both the Technion Research & Development ...
(Date:2/10/2016)... New York , February 10, 2016 ... Growth, Trends and Forecast 2015 - 2023 ", reveals that ... rather slow growth from 2015 to 2023 owing to patent ... a meager CAGR of 1.30% during the forecast period, the ... to US$38.9 bn in 2023. --> Antibacterial Drugs ...
(Date:2/10/2016)... 2016  Silicon Biosystems Menarini Inc., a developer ... uncover the biological complexities of disease at the ... of innovative technologies for genomics research, today announced ... enabling translational researchers to obtain high-quality sequencing results ... and normal cells in an optimized and seamless ...
Breaking Medicine Technology: